1361306-35-5

Upstream product

• 932042-98-3 2-bromo-3-vinylpyridine 
• 1190363-10-0 5-(2,3-difluorophenyl)cycloheptane-1,2-diol 
• 1190363-11-1 2-(tert-butyldimethylsilyloxy)-5-(2,3-difluorophenyl)cycloheptanol 
• 1190363-91-7 4-nitrophenyl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)-piperidine-1-carboxylate 
• 1190363-98-4 2-(1-(triisopropylsilyloxy)pent-4-enyl)-3-vinylpyridine 
• 1190363-36-0 (Z)-9-(triisopropylsilyloxy)-8,9-dihydro-7H-cyclohepta[b]pyridine 
• 1190363-38-2 6-bromo-9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-yl acetate epoxide 
• 1190363-39-3 9-(triisopropylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-6-ol 
• 1190363-40-6 9-(triisopropylsilyloxy)-8,9-dihydro-5H-cyclohepta[b]pyridin-6(7H)-one 
• 1190363-06-4 5-(2,3-difluorophenyl)nona-1,8-dien-5-ol 
• 1190363-41-7 (E)-9-(triisopropylsilyloxy)-8,9-dihydro-7H-cyclohepta[b]pyridin-6-yl trifluoromethanesulfonate 
• 1190363-42-8 (E)-6-(2,3-difluorophenyl)-9-(triisopropylsilyloxy)-8,9-dihydro-7H-cyclohepta[b]pyridine 
• 1190363-33-7 (E)-6-(2,3-difluorophenyl)-8,9-dihydro-7H-cyclohepta[b]pyridin-9-ol 
• 1190363-07-5 (Z)-1-(2,3-difluorophenyl)cyclohept-4-enol 

Relevant academic research and scientific papers

Discovery of BMS-846372, a potent and orally active human CGRP receptor antagonist for the treatment of migraine

Calcitonin gene-related peptide (CGRP) receptor antagonists have been clinically shown to be effective in the treatment of migraine, but identification of potent and orally bioavailable compounds has been challenging. Herein, we describe the conceptualization, synthesis, and preclinical characterization of a potent, orally active CGRP receptor antagonist 5 (BMS-846372). Compound 5 has good oral bioavailability in rat, dog, and cynomolgus monkeys and overall attractive preclinical properties including strong (>50% inhibition) exposure-dependent in vivo efficacy in a marmoset migraine model.